Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.45 |
| ▸ | CTSD | P07339 | 6/20 | 0.45 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284077 | 0.88 | BACE1 (0.51) | BACE1CTSDRENBACE2 | |
| SCHEMBL2284071 | 0.88 | BACE1 (0.51) | BACE1CTSDRENBACE2 | |
| SCHEMBL2287911 | 0.87 | BACE1 (0.49) | BACE1CTSDRENBACE2APP | |
| SCHEMBL2287917 | 0.87 | BACE1 (0.49) | BACE1CTSDRENBACE2APP | |
| SCHEMBL2281271 | 0.86 | BACE1 (0.53) | BACE1CTSDRENBACE2 | |
| SCHEMBL2281266 | 0.86 | BACE1 (0.53) | BACE1CTSDRENBACE2 | |
| SCHEMBL2280087 | 0.85 | BACE1 (0.48) | BACE1CTSDRENBACE2APP | |
| SCHEMBL2280091 | 0.85 | BACE1 (0.48) | BACE1CTSDRENBACE2APP | |
| SCHEMBL2280409 | 0.85 | BACE1 (0.50) | BACE1CTSDRENBACE2 | |
| SCHEMBL2280404 | 0.85 | BACE1 (0.50) | BACE1CTSDRENBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885CTSD 354/4885REN 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.